Novartis has offloaded two mid-phase mTORC1 inhibitors to PureTech Health in return for an equity stake and a source of future milestones and royalties.

Former FDA chief Califf leads a PCORI-backed research foundation, ex-Shire exec Shepard jumped to Eisai's oncology business, and Forty Seven hired former…

Shares in Ultragenyx weakened after a midpipeline drug candidate missed its targets in a trial for a rare genetic disorder.

In this week's EuroBiotech Report, AstraZeneca rejected by FDA, Novartis fails phase 3, Pulmocide raises $30 million and more.

Tessa Therapeutics has bought Euchloe Bio for its suite of checkpoint inhibitors.

BioLineRx has bought Agalimmune to expand its immuno-oncology pipeline. The takeover adds the synthetic alpha-gal immunotherapy AGI-134 to BioLineRx’s pipeline…

Former FDA commissioner Robert Califf, who was not asked back into his role by President Donald Trump, has become the new chair of the newly formed People-…

Akashi Therapeutics has been given the FDA go-ahead to restart tests for its Duchenne muscular dystrophy candidate HT-100 (delayed-release halofuginone), just…

Biotech